After big jumps, digoxin rollercoaster falls 82% in Q3 ASP drug pricing
Prices in the latest quarterly average sales price (ASP) drug pricing files from CMS were generally up, with only a few really spectacular changes — including a breathtaking price drop on a popular heart drug that had been skyrocketing in recent years.
To read the full article, sign in and subscribe to the DecisionHealth Newsletters.